1.Pharmacogenomics screening of HLA-B*1502 in epilepsy patients: How we do it in the UKM Medical Centre, Malaysia
Sue-Mian Then ; Zam Zureena Mohd Rani ; Azman Ali Raymond ; Rahman Jamal
Neurology Asia 2013;18(s1):27-29
Previous studies have shown that carbamazepine-induced Stevens-Johnson syndrome (SJS) and
toxic epidermal necrolysis (TEN) patients is associated with the HLA-B*1502 allele. Screening for
HLA-B*1502 before using carbamazepine can prevent SJS/TEN particularly in populations with high
frequency of the allele. The objective of this paper was to describe how the UKM Medical Centre,
Malaysia was able to set up a cost effective screening of HLA-B*1502 for patients taking carbamazepine.
The cost of in-house HLA-B⁄1502 screening was less than those commercially available, and was
sensitive and specifi c.
2.HLA-B*15:02 screening in epileptic patients using a high resolution melting-real time PCR (HRM-QPCR) method
Zam Zureena Mohd Rani ; Nor Azian Abdul Murad ; Sue-Mian THEN ; Suthashini Panja BERNAM ; Asmaa ABDULLAH ; Saberi SAIMUN ; Sri Noraima OTHMAN ; Raymond Azman ALI ; Rahman JAMAL
Neurology Asia 2018;23(2):137-144
Background: The HLA-B*15:02 polymorphism in epileptic patients is known to be associated with carbamazepine-induced Stevens-Johnson syndrome (SJS). The prevalence of HLA-B*15:02 polymorphism seemed to be ethnic-specific with a higher frequency of HLA-B*15:02 in Asian compared to the Europeans. This study was performed to determine the frequency of the HLA-B*15:02 polymorphism in epileptic patients at the Chancellor Tuanku Muhriz Hospital-UKM Medical Centre (HCTM-UKMMC) using high resolution melting-real time PCR (HRM-QPCR) method. Methods: We performed a fast and effective in-house high resolution melting-real time polymerase chain reaction method and compared it with the conventional multiplex-PCR method. The specificity and sensitivity of each test were also determined using DNA from saliva. Results: Using the conventional multiplex-PCR approach for screening, 25 out of 64 (39.1%) epileptic patients were positive for HLA-B*15:02. However, using the HRM-QPCR technique, 24/64 (37.5%) of the patients were positive. The one patient who tested positive by the multiplex-PCR but negative using the HRM-QPCR turned out to be negative by DNA sequencing. The HRM-QPCR and DNA sequencing showed 100% sensitivity and specificity. The multiplex-PCR showed 100% sensitivity and 98.4% specificity compared to both HRM-QPCR and DNA sequencing. The HRM-QPCR is also more cost-effective (<$16.40 USD/test) and less time-consuming when compared to the multiplex-PCR ($25.15 USD/test).Conclusion: Our result suggested that multiplex PCR, HRM-QPCR and Sanger sequencing can be used for detection of HLA-B*15:02. However, a qualitative method such as multiplex PCR should be confirmed with other quantitative methods such as HRM-QPCR and Sanger sequencing.